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Abstract
Pharmacokinetic analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) time-course data
allows estimation of quantitative parameters such as K trans (rate constant for plasma/interstitium contrast agent
transfer), ve (extravascular extracellular volume fraction), and vp (plasma volume fraction). A plethora of factors in
DCE-MRI data acquisition and analysis can affect accuracy and precision of these parameters and, consequently,
the utility of quantitative DCE-MRI for assessing therapy response. In this multicenter data analysis challenge,
DCE-MRI data acquired at one center from 10 patients with breast cancer before and after the first cycle of neo-
adjuvant chemotherapy were shared and processed with 12 software tools based on the Tofts model (TM),
extended TM, and Shutter-Speed model. Inputs of tumor region of interest definition, pre-contrast T1, and arterial
input function were controlled to focus on the variations in parameter value and response prediction capability
caused by differences in models and associated algorithms. Considerable parameter variations were observed
with the within-subject coefficient of variation (wCV) values for K trans and vp being as high as 0.59 and 0.82,
respectively. Parameter agreement improved when only algorithms based on the same model were compared,
e.g., the K trans intraclass correlation coefficient increased to as high as 0.84. Agreement in parameter percentage
change was much better than that in absolute parameter value, e.g., the pairwise concordance correlation
coefficient improved from 0.047 (for K trans) to 0.92 (for K trans percentage change) in comparing two TM algorithms.
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Nearly all algorithms provided good to excellent (univariate logistic regression c-statistic value ranging from 0.8 to
1.0) early prediction of therapy response using the metrics of mean tumor K trans and kep (=K
trans/ve, intravasation
rate constant) after the first therapy cycle and the corresponding percentage changes. The results suggest that the
interalgorithm parameter variations are largely systematic, which are not likely to significantly affect the utility of
DCE-MRI for assessment of therapy response.
Translational Oncology (2014) 7, 153–166
Introduction
With advances in targeted molecular therapy for cancer treatment,
change in tumor size in response to therapy, which is routinely used
in standard care for therapeutic monitoring, is often found to mani-
fest later than changes in underlying tumor characteristics [1–8],
such as vascularization and vascular permeability, cellularity, metab-
olism, and biochemistry. Thus, imaging modalities that can quantify
tumor functions are becoming increasingly important for evaluation
and prediction of therapy response. Dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI) is a minimally invasive
imaging method that measures changes in tissue microvascular prop-
erties and has been widely used in research or early phase clinical trial
settings to provide assessment of tumor therapeutic response [1–8],
as many cancer drugs affect tumor vasculature directly or indirectly
[9]. The quantitative approach for DCE-MRI data analysis using
pharmacokinetic models allows extraction and mapping of quanti-
tative parameters of tumor biology in vivo. These parameters are
usually variants of K trans, a rate constant for contrast agent (CA)
molecule plasma/interstitium transfer, ve, the volume fraction of
interstitial space (extracellular and extravascular, the putative CA dis-
tribution volume), and vp, the plasma volume fraction. The CA
intravasation rate constant, kep, can be calculated as K
trans/ve. Recent
workshops on both sides of the Atlantic have generated guidelines
and recommendations on acquisition and analysis of DCE-MRI data
for the purpose of assessing tumor therapy response [9–11].
Unlike qualitative (such as description of curve shape) or semi-
quantitative (such as calculation of maximum signal change) analysis,
the parameters derived from pharmacokinetic modeling of DCE-
MRI time-course data should, in principle, be independent of
MRI scanner platform (vendor and field strength), data acquisition
details (pulse sequence and parameters), CA dose and/or injection
rate, personnel skills, and so on, which makes them desirable imaging
end points in multicenter clinical trial studies. However, the accuracy
and precision of these parameters can be affected by a plethora of
factors, including errors in quantification of pre-contrast T1 [12–15]
and determination of arterial input function (AIF) [4,9,16,17],
inadequate temporal resolution [9,18,19] or signal-to-noise ratio [15],
as well as selection of models to fit the data [9,20,21]. A recent study
[22] comparing four commercial software packages for quantitative
DCE-MRI data analysis has revealed considerable variability in
pharmacokinetic parameter quantification from data sets of 15 subjects,
with up to 74% within-subject coefficient of variation (wCV) among
the tools, even though all four software packages were presumably based
on the same Tofts model (TM) [23]. Commercialization of software
tools for kinetic modeling of DCE-MRI data represents a necessary
step for wide dissemination of DCE-MRI as a quantitative imaging bio-
marker in clinical trials and general practice. However, the poor repro-
ducibility shown by this study among the available commercial solutions
is one of the major obstacles in integration of quantitative DCE-MRI
into standard care. Thorough comparison and validation of algorithms/
software tools for DCE-MRI data analysis are necessary within the
context of monitoring tumor response to therapy.
Recognizing the importance of quantitative imaging for assessment
of cancer response to therapy and rapid evaluation of the efficacy
of new anticancer drugs, the National Cancer Institute has recently
established the Quantitative Imaging Network (QIN) to provide
resources for developing and validating quantitative imaging tools.
The main mission of the QIN Image Analysis and Performance
Metrics Working Group is to provide guidance and reach consensus
on quantitative image analysis methods through comparison and
validation of analysis algorithms. The available QIN infrastructure
facilitates collaborative challenge projects involving multiple QIN
centers. Here, we report the results from a DCE-MRI data analysis
challenge project, in which several QIN centers performed analyses
of DCE-MRI data from a digital reference object (DRO) [24] and
human breast tumors using site-specific employment of algorithms/
software tools. The overall goal of the project was to compare and
validate DCE-MRI data analysis tools available within the QIN.
Because ultimately the utility of a quantitative imaging method for
assessing cancer therapy response is judged by its robustness in
evaluation/prediction of clinical and/or pathologic end points of
response, the DCE-MRI pharmacokinetic parameters and their
changes following therapy were correlated with pathologic response
status of the patients with breast cancer to compare the capabilities of
the algorithms/tools in predicting complete response versus non-
complete response.
Materials and Methods
DCE-MRI Challenge Participating QIN Centers
The QIN centers that participated in this DCE-MRI data analysis
challenge project are Oregon Health and Science University (OHSU),
VanderbiltUniversity (VU),University of Pittsburgh (UP), Brigham and
Women’s Hospital (BWH) and in collaboration with General Electric
Research and Development (BWH-GE), University of Michigan
(UM), University ofWashington (UW), and Icahn School ofMedicine
at Mount Sinai (ISM).
Simulated DRO DCE-MRI Data Sharing and Analysis
A software phantom or DRO with known pharmacokinetic param-
eter values can be an effective means to compare and validate different
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DCE-MRI data analysis packages by providing a reference. The
Quantitative Imaging Biomarker Alliance (QIBA) and Duke Uni-
versity have generated a variety of simulated DCE-MRI data sets
using a matrix of parameter values [24]. For this challenge project,
the DRO data of the QIBA_v6_Tofts version [25] were made avail-
able to the participating QIN centers. The DRO data (Figure 1) were
constructed with 30 combinations of six K trans (0.01, 0.02, 0.05, 0.1,
0.2, and 0.35 min−1) and five ve (0.01, 0.05, 0.1, 0.2, and 0.5) values
according to the TM [23] and consisted of a single image slice of
simulated DCE-MRI signal intensity time-course data (with 0.5-
second temporal resolution) without noise in DICOM format with
headers for both Siemens and GE scanner platforms. Each K trans
and ve combination occupied a 10 × 10 pixel square area of the slice,
allowing evaluation of reproducibility in fitting pixel data with the
same K trans and ve combination. Details of simulated data acquisition
parameters and fixed parameters used for the TM can be found in
references [24] and [25].
The DRO data were downloaded from the Duke University
websites [24] and, with permission of the creators, stored at a secure
website (with help from the QIN Bioinformatics Working Group)
for download by the participating QIN sites. Before proceeding to
analyze the human breast DCE-MRI data, the participating sites
were asked to process the simulated DRO DCE-MRI data using
their TM-based algorithms/software tools with the purpose of vali-
dating the mathematical formulations implemented in the TM algo-
rithms. The results of DRO data analyses were submitted as parametric
maps in Matlab, Nifti, or Nrrd formats.
Human Breast DCE-MRI Data Acquisition and Sharing
As part of the quantitative imaging studies at OHSU as an individual
QIN center, breast DCE-MRI data were acquired with consent from
patients with locally advanced breast cancer who underwent preoperative
neoadjuvant chemotherapy (NACT). Four DCE-MRI sessions were
undertaken during the treatment course: pre-NACT (visit 1, V1), after
the first cycle of NACT (visit 2, V2), at a NACT midpoint (usually
after the third NACT cycle; visit 3), and after the completion of NACT
(visit 4). The study was conducted under the approval of the local Insti-
tutional Review Board (IRB). For this challenge project, the V1 and V2
data sets from 10 of 16 consecutive patients were shared among the
participating QIN sites. The data from the other six patients were
not selected because either the V2 data were not acquired or severe
motion degraded data quality at V1 and/or V2. All breast MRI studies
were performed using a Siemens 3T system with a body coil and a
four-channel bilateral phased-array breast coil as the transmitter and
receiver, respectively. Following pilot scans and pre-CA T2-weighted
MRI with fat saturation and T1-weighted MRI without fat satura-
tion, axial bilateral DCE-MRI images with fat saturation and full
breast coverage were acquired with a three-dimensional (3D) gradient
echo-based Time-resolved angiography WIth Stochastic Trajectories
(TWIST) sequence, which employs the strategy of k-space under-
sampling during acquisition and data sharing during reconstruction
[26,27]. DCE-MRI acquisition parameters included 10° flip angle,
2.9/6.2 millisecond echo time/repetition time (TE/TR), a parallel im-
aging acceleration factor of two, 30 to 34 cm field of view (FOV), 320 ×
320 in-plane matrix size, and 1.4-mm slice thickness. The total acqui-
sition time was ∼10 minutes for 32 to 34 image volume sets of 112
to 120 slices each with 18- to 20-second temporal resolution. The
CA Gd(HP-DO3A) [ProHance] IV injection (0.1 mmol/kg at 2 ml/s)
by a programmable power injector was timed to commence after
acquisition of two baseline image volumes, followed by a 20-ml saline
flush. Breast tumor regions of interest (ROIs) were drawn by experienced
OHSU breast radiologists on post-CA multislice images covering the
contrast-enhanced tumor.
For DCE-MRI data sharing, the V1 and V2 raw data sets in
Matlab, Nifti, and DICOM formats together with the registered pre-
drawn tumor ROIs from the 10 patients—a total of 20 data sets—were
uploaded to the same secure website that housed the DRO data and
downloaded by the participating sites. Since the human MRI data were
acquired under strictly coded names (e.g., “BreastChemo1” as the last
name and “Visit 1” as the first name) and without any entries of
identifiable patient health information, no patient health informa-
tion was ever shared among the QIN sites. The sharing of the anony-
mous human breast MRI data within the QIN was approved by
the OHSU IRB.
Human Breast DCE-MRI Data Analysis
The pharmacokinetic models used by the participating sites
for breast tumor DCE-MRI data analysis generally fell into the
Figure 1. Two-dimensional image view of the arrays of K trans (A) and ve (B) values used to construct the simulated DRO DCE-MRI
data without noise. Each color stripe represents one of six K trans (0.01, 0.02, 0.05, 0.1, 0.2, and 0.35 min−1) (A) or one of five ve
(0.01, 0.05, 0.1, 0.2, and 0.5) (B) values. The numbers along the x- and y-axes represent pixel numbers in both panels. Combination
of the two panels results in 30 squares with 10 × 10 pixels each, representing the possible 30 combinations of K trans and ve values
for simulated DRO data.
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following three categories: the TM [23], the extended TM (ETM)
[28,29], and the fast exchange regime (FXR)–allowed Shutter-
Speed Model (SSM) [17,30]. Equations 1, 2, and 3 below represent
the basic formulations for the TM, ETM, and FXR-SSM, respectively:
CtðtÞ = K trans
Z t
0
Cpðt′Þexp ð−K trans=veðt − t′ÞÞdt′; ð1Þ
CtðtÞ = K trans
Z t
0
Cpðt′Þexp ð−K trans=veðt − t′ÞÞdt′ + vpCpðtÞ; ð2Þ
R1*ðtÞ = ð1=2Þ½f2R1i + r1 K trans=ve
Z t
0
Cpðt′Þexpð−K trans=veðt − t′ÞÞdt′
+ ðR10 − R1i + 1=τiÞ=veg − f½2=τi + ðR1i −R10 − 1=τiÞ=ve
− r1K trans=ve
Z t
0
Cpðt′Þexpð−K trans=veðt − t′ÞÞdt′2
+ 4ð1 − veÞ=τ2i veg
1=2; ð3Þ
where C t(t) represents tissue CA concentration at time t; Cp(t′) is the
arterial plasma CA concentration time course, or AIF; R1*(t) is the tis-
sue apparent longitudinal relaxation rate constant; R1i is the intracellu-
lar longitudinal relaxation rate constant; R10 is the pre-CA tissue R1; r1
is the tissue CA relaxivity; and τi is the mean intracellular water mole-
cule lifetime. Both the TM and ETM neglect the finite intercompart-
mental water exchange kinetics, assuming the system is in the fast
exchange limit condition. As a result, R1(t) [or R1*(t)] is linearly related
to C t(t):
R1ðtÞ = r1CtðtÞ + R10: ð4Þ
The SSM accounts for the finite water exchange kinetics during the CA
passage through the tissue of interest, and consequently, R1(t) is not
linearly related to C t(t). The FXR version is a two-compartment
three-parameter (extracellular and intracellular compartments; K trans,
ve, and τi) SSM, taking into account transcytolemmal water exchange
kinetics but assuming single exponential longitudinal MR signal decay
[17,30].
Each QIN site had the option of using one or more models for
DCE-MRI time-course data fitting. This challenge project focuses
on comparisons of different pharmacokinetic models and associated
software packages for therapy response assessment. Therefore, to
minimize variations in derived kinetic parameters caused by factors
other than differences in models and algorithms, such as uncertain-
ties in AIF determination and R10 quantification, a population-
averaged AIF was provided to each site for analysis of all 20 data sets
and the R10 value was given for each of the 20 studies. The population-
averaged AIF was obtained by averaging individually measured AIFs
from an axillary artery in a previous sagittal breast DCE-MRI study
[31–33], which employed the same CA injection protocol, including
dose, injection rate, and injection site (antecubital vein). The average
R10 value for each tumor was determined by comparing signal inten-
sities of pre-CA baseline DCE images with those of the spatially regis-
tered proton density images acquired just before DCE-MRI [27] and
was used for kinetic modeling of tumor ROI or pixel (within the ROI)
DCE data by each site. In addition, the tumor ROI definitions on
multiple image slices covering the tumor were also provided for each
data set (see above).
The data analysis tools used by the participating sites included
software packages built in-house, obtained as free open source, or
purchased commercially, as well as prototype research software under
development by GE. For results reporting, each site was required
to provide mean tumor ROI pharmacokinetic parameter values, the
corresponding percentage changes (V2 relative to V1, V21), and
parametric maps. Some sites calculated the mean tumor ROI param-
eters by fitting ROI time-course data from each slice and then averaging
the derived slice ROI parameter values, while the others computed
Table 1. Details of Pharmacokinetic Analysis of Human Breast DCE-MRI Data at Participating Sites.
Characteristics OHSU VU UP UM UW ISM BWH-GE BWH-3D Slicer
Selected models TM, FXR-SSM TM, ETM,
FXR-SSM
TM ETM ETM TM TM, ETM TM
Returned parameters K trans, ve, kep,
τi (SSM only)
K trans, ve, kep,
vp (ETM only),
τi (SSM only)
K trans, ve, kep K
trans, ve, kep, vp K
trans, ve, kep, vp K
trans, ve, kep K
trans, ve, kep,
vp (ETM only)
K trans, ve, kep
Software origin
and platform
In-house Matlab In-house Matlab,
IDL
In-house Matlab In-house Matlab In-house and
commercial*
In-house Matlab Research prototype
for commercialization
Open source
3D Slicer†
Tumor ROI definition Provided Provided Provided Provided Provided Provided Provided Provided
〈AIF〉 Provided Provided Provided Provided Provided Provided Provided Provided
〈R10〉 Provided Provided Provided Provided Provided Provided Provided Provided
Motion correction NA NA NA NA NA NA NA NA
CA arrival
time estimation
Site-specific Site-specific Site-specific Site-specific Site-specific Site-specific Site-specific Site-specific
Model goodness
of fit
Site-specific Site-specific Site-specific Site-specific Site-specific Site-specific Site-specific Site-specific
Mean tumor ROI
parameter calculation‡
Averaging slice
ROI values
Averaging pixel
values
Averaging slice
ROI values
Averaging pixel
values
Averaging slice
ROI values
Averaging slice
ROI values
Averaging pixel
values
Averaging pixel
values
〈AIF〉, population-averaged AIF; 〈R10〉, average pre-contrast longitudinal relaxation rate constant.
*In-house Matlab script was generated to load image data and covert ROI signal intensity time course to CA concentration time course, which was then fit with the ETM using a commercial software
package, PMOD (PMOD Technologies Ltd., Zurich, Switzerland).
†Free open source extension for 3D Slicer, http://www.slicer.org/slicerWiki/index.php/Documentation/4.3/Modules/PkModeling.
‡“Averaging slice ROI values”: Slice ROI parameter value was obtained by fitting tumor ROI DCE-MRI data from the slice, and these values from all slices covering the targeted tumor were then
averaged; “averaging pixel values”: Pixel parameter value was obtained by fitting pixel DCE-MRI data, and these values from all pixels within all tumor ROIs were then averaged.
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those by averaging pixel parameter values obtained from fittings of
all pixel time-course data. The details of pharmacokinetic analyses
performed by each site from model selection to mean parameter
calculation are summarized in Table 1.
Determination of Pathologic Response Status
The pathologic response (to NACT) status of each patient with
breast cancer was determined by pathologic analyses and comparisons
of the pre-NACT core biopsy specimen with the post-NACT resection
specimen. The two previously published and validated indices [34,35]
were measured: Relative Change in Tumor Density (RCTD) and
Residual Cancer Burden. A pathologic complete response (pCR) is
defined as the absence of residual tumor (RCTD = −1.0; Residual
Cancer Burden = 0). A pathologic nonresponse (pNR) is defined as
tumor cell density in resection specimen equal to or greater than that
in core biopsy specimen (RCTD ≥ 0). Pathologic partial response
is defined as findings intermediate between pCR and pNR. For this
study, the binary classification of pCR and non-pCR (pNR and
pathologic partial response) was used for the 10-patient cohort.
Statistical Analysis
For DRODCE-MRI data analysis, the estimatedK trans and ve values
from data fitting using site-specific TM algorithms were compared to
the simulated “true” K trans and ve values that were used to construct
the DRO data.
For human breast DCE-MRI data analysis, descriptive statistical
analysis was conducted to summarize the pharmacokinetic parameter
values returned by each algorithm/software tool. To assess the reproduc-
ibility of each parameter across all algorithms and within each model
(i.e., TM, ETM, or SSM), linear mixed models were fit to obtain the
maximum likelihood estimates of the intraclass correlation coefficient
(ICC) and wCV, and their corresponding 95% confidence intervals
(CIs). The concordance correlation coefficients (CCCs) and the
corresponding 95% CIs were estimated to represent the level of pairwise
linear agreement to a 45° line of which the intercept is forced to be
zero. Linear mixed models were fit to determine whether the parameter
mean differs for pairwise comparisons of the three kinetic models.
Univariate logistic regression (ULR) models were fit to compute the
c-statistic, a measure equivalent to the area under the Receiver Operating
Characteristic curve, to reflect the predictive ability of each parameter
for tumor therapy response. While logarithm transformation will help
address the skewed distribution of some parameters, the analysis results
are rather robust to using values with or without transformation. There-
fore, the original parameter values returned from all algorithms were
used for statistical analysis throughout, which was conducted using
SAS 9.3 (Cary, NY). SAS macro %ICC9 and %mccc were used for
estimations of ICC, wCV, and CCC.
Results
DRO DCE-MRI Data Analysis
DRO data analyses by five of six TM algorithms/software packages
used in this challenge generally returned fairly accurate K trans and
ve values with <10% errors for both parameters compared to the
simulated values. The exceptions occurred in the lower left area
of the simulated K trans and ve arrays (Figure 1), where high K
trans
and low ve values are combined—the errors for the estimated param-
eters were the highest for the combination of K trans = 0.35 min−1
and ve = 0.01. As an example, Figure 2 shows the 2D arrays of
the estimated K trans (Figure 2A) and ve (Figure 2B) values obtained
with the OHSU TM algorithm. The highest error can be clearly
seen in the lower left square of the K trans array (Figure 2A), which
Figure 2. Two-dimensional image view of the arrays of estimated K trans (A) and ve (B) values obtained by fitting the DRO data with the
TM algorithm implemented at OHSU. Good agreements are seen between the estimated K trans (A) and simulated “true” K trans
(Figure 1A) values except for in the lower left areas of the panel with high K trans and low ve combinations. There are no visible differences
seen between the estimated ve (B) and simulated “true” ve (Figure 1B) values.
Figure 3. The estimated K trans values obtained by fitting the DRO
data with the TM algorithm implemented at ISM are plotted
against the simulated “true” K trans values at five simulated ve values.
The straight line is the line of unity, representing perfect agreement
between the estimated and simulated K trans values.
Translational Oncology Vol. 7, No. 1, 2014 Variation of DCE-MRI in Assessing Therapy Response Huang et al. 157
Figure 4. (A) Box plots of V1 (left column) and V2 (right column) mean tumor K trans, ve, kep, vp, and τi values from the 10 patients with
breast cancer. (B) Box plots of percentage changes (V2 relative to V1) of the five parameters. The central bar and diamond symbols
represent the median and mean values, respectively. K trans, ve, and kep are obtainable with all three pharmacokinetic models: TM, ETM,
and SSM. The box plots associated with the same model are grouped together: institution abbreviations are labeled in the V1 K trans
panel, while themodel abbreviations are labeled in the V2 K trans panel. The same labeling orders also apply to the V1 and V2 ve and kep panels
in A and K trans, ve, and kep percentage change panels in B. With the models used in this study, the vp and τi parameters can be derived only
with the ETM and SSM, respectively. The institution labeling orders in V1 vp and τi panels (A) apply to the V2 vp and τi panels in A and
vp and τi percentage change panels in B, respectively.
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represents an estimated K trans value of 0.27 min−1, 23% smaller
than the simulated value of 0.35 min−1. The estimated ve value in
the same square is 11% smaller than the simulated value of 0.01.
However, the error is not clearly identifiable in the ve array (Figure 2B)
due to the small absolute value of the error (0.01 × 11% = 0.0011). The
pattern of uniform color in each square of 10 × 10 pixels indicates
high reproducibility of the OHSU TM algorithm in analyzing pixel
DCE-MRI time-course data constructed with the same K trans and
ve combination. Figure 3 shows a scatter plot of estimated K
trans
versus simulated K trans values based on results obtained with the
ISM TM algorithm, illustrating nearly the same pattern of estimated
K trans values as that generated by the OHSU TM algorithm (Fig-
ure 2A): good agreement between estimated and simulated K trans values
except for where ve = 0.01 and K
trans ≥ 0.2 min−1, and the error
increases with K trans value. All five TM software packages generated
consistent maximum errors at the simulated combination of K trans =
0.35 min−1 and ve = 0.01: −23% for K
trans and −11% for ve.
Human Breast DCE-MRI Analysis
As summarized in Table 1, the V1 and V2 DCE-MRI data from the
10 patientswere processed by seven institutions using 12 pharmacokinetic
analysis algorithms: 6 TM (OHSU, VU, UP, ISM, BWH-GE, and
BWH-3D Slicer [36]), 4 ETM (VU, UM, UW, and BWH-GE), and
2 SSM (OHSU and VU).
Variance analysis. Figure 4A shows the box plots of mean tumor
K trans, ve, and kep values at V1 and V2 obtained using all 12 algo-
rithms, vp values from the 4 ETM algorithms, and τi values from
the 2 SSM algorithms only, whereas Figure 4B displays the box plots
of percentage changes (V21) of the same parameters. Considerable
Figure 4. (continued).
Figure 5. Column graph of mean wCV for K trans, ve, kep, vp, and τi
parameters at V1 (blue) and V2 (red) obtained with all 12 algorithms.
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variations are observed for all returned parameters at V1 or V2 across
different algorithms with the K trans and ve values returned by the
SSM algorithms (e.g., range at V1: K trans, 0.047-0.25 min−1; ve,
0.32-0.66) generally larger than those returned by either the TM
(range at V1: K trans, 0.0090-0.14 min−1; ve, 0.066-0.55) or the
ETM (range at V1: K trans, 0.019-0.15 min−1; ve, 0.16-0.48) algo-
rithms. Interestingly, the percentage changes of the DCE-MRI param-
eters (Figure 4B) show substantial improvement in stability across all
the software tools, e.g., the range of the mean values of K trans percent-
age change obtained from the 12 algorithms is relatively small: −13%
to −28%.
Figure 5 shows the column graphs of wCV for all five parameters
at V1 and V2. wCV cannot be calculated for percentage changes
because negative values are not allowed. A smaller wCV value indi-
cates less variation in measurements on the same subject by different
approaches. In this study, the wCV values range from 0.25 for τi at
V2 to 0.82 for vp at V1. Among the five DCE-MRI parameters, the
vp parameter obtained with the ETM shows the largest variations.
Table 2 lists the K trans ICC and the corresponding 95% CI values
for comparisons of all 12 algorithms, TM only, ETM only, and SSM
only. ICC represents the proportion of total variation contributed by
between-subject difference, with high ICC indicating good agreement
among different measurement approaches. The ICC values are gen-
erally lower when all 12 software tools are compared as opposed to
only algorithms within the same model are compared. It is notable
in Table 2 that percentage change of K trans generally has higher
ICC values than absolute K trans value at either V1 or V2. The same
patterns are observed for the other parameters (results not shown
here). Among all the parameters, vp has the lowest ICC values of
0.09, 0.04, and 0.11 for V1, V2, and percentage change, respectively.
Concordance analysis. Concordance correlation analysis was
conducted to assess parameter agreement between any two algorithms
within the same pharmacokinetic model (TM, ETM, or SSM). Table 3
tabulates the K trans CCC and 95% CI values for any combination of
two algorithms belonging to the same pharmacokinetic model. Though
the CCC values can be as low as 0.047 for V2 K trans between two TM
software tools, those for K trans percentage change are consistently high
—many are greater than 0.9. Similar patterns are also observed for kep,
but not for ve, vp, and τi. Table 4 lists the ranges of the CCC values for
Table 2. Ktrans ICC.
Algorithm Comparison V1 V2 % Change (V21)
All algorithms (n = 12) 0.27 (0.11, 0.53) 0.18 (0.06, 0.44) 0.69 (0.46, 0.85)
TM (n = 6) 0.44 (0.20, 0.71) 0.17 (0.04, 0.54) 0.91 (0.79, 0.96)
ETM (n = 4) 0.62 (0.34, 0.84) 0.36 (0.11, 0.71) 0.63 (0.34, 0.84)
SSM (n = 2) 0.84 (0.58, 0.95) 0.72 (0.36, 0.92) 0.89 (0.69, 0.97)
% Change (V21), percentage change (V2 relative to V1).
The two numbers in parenthesis represent 95% CIs.
Table 3. CCC for Ktrans within the TM, ETM, or SSM.
V1 V2 % Change (V21)
TM
OHSU_TM and VU_TM 0.870 (0.597, 0.962) 0.734 (0.318, 0.913) 0.886 (0.634, 0.968)
OHSU_TM and ISM_TM 0.968 (0.896, 0.991) 0.807 (0.509, 0.932) 0.868 (0.600, 0.961)
OHSU_TM and BWH-GE_TM 0.512 (0.127, 0.763) 0.295 (0.012, 0.534) 0.911 (0.723, 0.974)
OHSU_TM and UP_TM 0.981 (0.940, 0.994) 0.911 (0.705, 0.975) 0.899 (0.683, 0.971)
OHSU_TM and BWH-3D Slicer_TM 0.179 (−.065, 0.404) 0.058 (−.060, 0.175) 0.781 (0.406, 0.931)
VU_TM and ISM_TM 0.850 (0.592, 0.950) 0.538 (0.161, 0.778) 0.972 (0.912, 0.991)
VU_TM and BWH-GE_TM 0.403 (0.121, 0.625) 0.212 (0.025, 0.384) 0.961 (0.873, 0.989)
VU_TM and UP_TM 0.883 (0.624, 0.967) 0.683 (0.206, 0.898) 0.959 (0.860, 0.988)
VU_TM and BWH-3D Slicer_TM 0.125 (−.023, 0.268) 0.047 (−.028, 0.121) 0.922 (0.776, 0.974)
ISM_TM and BWH-GE_TM 0.598 (0.229, 0.817) 0.438 (0.087, 0.692) 0.978 (0.922, 0.994)
ISM_TM and UP_TM 0.934 (0.820, 0.976) 0.840 (0.620, 0.937) 0.985 (0.947, 0.996)
ISM_TM and BWH-3D Slicer_TM 0.198 (−.044, 0.417) 0.081 (−.053, 0.213) 0.953 (0.839, 0.987)
BWH-GE_TM and UP_TM 0.447 (0.088, 0.703) 0.269 (−.009, 0.508) 0.980 (0.926, 0.994)
BWH-GE_TM and BWH-3D Slicer_TM 0.386 (0.102, 0.612) 0.186 (−.001, 0.361) 0.938 (0.792, 0.983)
UP_TM and BWH-3D Slicer_TM 0.156 (−.063, 0.361) 0.056 (−.060, 0.172) 0.922 (0.743, 0.978)
ETM
VU_ETM and UM_ETM 0.822 (0.479, 0.947) 0.715 (0.229, 0.916) 0.795 (0.416, 0.939)
VU_ETM and BWH-GE_ETM 0.710 (0.310, 0.897) 0.247 (0.007, 0.460) 0.650 (0.151, 0.885)
VU_ETM and UW_ETM 0.591 (0.012, 0.874) 0.428 (−.192, 0.803) 0.424 (−.224, 0.812)
UM_ETM and BWH-GE_TM 0.570 (0.090, 0.835) 0.417 (0.114, 0.649) 0.787 (0.392, 0.937)
UM_ETM and UW_ETM 0.597 (0.024, 0.875) 0.546 (−.044, 0.853) 0.546 (−.062, 0.858)
BWH-GE_ETM and UW_ETM 0.616 (0.161, 0.855) 0.391 (−.098, 0.728) 0.804 (0.429, 0.943)
SSM
OHSU_SSM and VU_SSM 0.859 (0.592, 0.956) 0.761 (0.445, 0.908) 0.902 (0.679, 0.972)
% Change (V21), percentage change (V2 relative to V1).
The two numbers in parenthesis represent 95% CIs.
Note: The institution abbreviation is listed ahead of the model abbreviation.
Table 4. Range of Pairwise CCC for ve, kep, vp, and τi.
Parameter Algorithm Comparison V1 V2 % Change (V21)
ve TM (n = 6) 0.020-0.885 0.414-0.965 0.062-0.914
ETM (n = 4) 0.246-0.891 0.407-0.931 0.132-0.969
SSM (n = 2) 0.175-0.175 0.456-0.456 0.432-0.432
kep TM (n = 6) 0.030-0.782 0.267-0.973 0.754-0.992
ETM (n = 4) 0.069-0.792 0.183-0.882 0.571-0.913
SSM (n = 2) 0.134-0.134 0.530-0.530 0.511-0.511
vp ETM (n = 4) 0.108-0.764 0.077-0.407 0.087-0.909
τi SSM (n = 2) 0.437-0.437 0.461-0.461 0.067-0.067
% Change (V21), percentage change (V2 relative to V1).
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ve, kep, vp, and τi. The ve, kep, and vp parameters all have large CCC
ranges at V1 and V2, but only the kep percentage change has a much
tighter CCC range for either the TM or ETM. Note that comparison
of the two SSM algorithms generated only one CCC value.
Comparison of model parameter mean values. Table 5 shows the
P values for comparisons of the mean DCE-MRI parameters (at V1
and V2, and percentage change) between the three kinetic models
using the mixed-models method. Only the means of K trans, ve, and
kep were compared because each model used in this study generates
these three parameters. Figure 6 shows the box plots of these three
parameters stratified by the models at V1 and V2. Clearly, the K trans
and ve values returned by the SSM are substantially greater than
those returned by either the TM or ETM, and the differences are
statistically significant with very small P values (<.0001 for either
TM vs SSM or ETM vs SSM at V1 or V2). It is important to note that
despite the significant differences in absolute K trans values at V1 and
V2, there are no statistically significant differences in K trans percentage
change between the SSM and TM or ETM. For kep, except for the
TM versus SSM comparison of its percentage change, there are no
statistically significant differences in its value or percentage change
between the models.
Table 5. P Values for Pairwise Comparison of the Mean DCE-MRI Parameter across Three Kinetic Models.
Parameter V1 V2 % Change (V21)
TM versus ETM TM versus SSM ETM versus SSM TM versus ETM TM versus SSM ETM versus SSM TM versus ETM TM versus SSM ETM versus SSM
K trans .2479 <.0001 <.0001 .0447 <.0001 <.0001 .1016 .5382 .697
ve <.0001 <.0001 <.0001 .1659 <.0001 <.0001 .0658 .0049 .0067
kep .1197 .6602 .1704 .8428 .1465 .2289 .0985 .0345 .2594
% Change (V21), percentage change (V2 relative to V1).
Figure 6. Box plots of mean tumor K trans, ve, and kep values obtained with algorithms based on the TM (six algorithms), ETM (four
algorithms), and SSM (two algorithms) at V1 (left column) and V2 (right column). The central bar and diamond symbols represent the
median and mean values, respectively. The TM, ETM, and SSM labeling orders in the V1 K trans plot apply to all the other plots.
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Early prediction of pCR. The pathologic reviews of the patients’
resection and pre-NACT biopsy specimens revealed that in this cohort,
three patients achieved pCR following NACT, while the other seven
were non-pCRs (all pPRs). The ULR c-statistic values for early dis-
crimination of pCR and non-pCR are listed in Table 6 for each
DCE-MRI parameter (obtained from multiple algorithms) at V1 and
V2, as well as its percentage change. None of the parameters at V1
(pre-NACT) provides good (0.8 ≤ c < 0.9) to excellent (0.9 ≤ c ≤ 1.0)
prediction of response, except for a very few cases: ve of OHSU_TM
(c = 0.81), kep of BWH-GE_TM and BWH-GE_ETM (both c =
0.81), vp of UM_ETM (c = 0.857), and τi of OHSU_SSM (c =
0.857). However, nearly all algorithms from participating QIN
centers achieve good to excellent early discriminations of pCR and
non-pCR using the K trans and kep parameters at V2 and their per-
centage changes (V21), with majority having c values equal to 1
(indicating complete separation of pCR and non-pCR) or greater
than 0.9. Both ve and vp parameters, at V2 or their percentage
changes, are not reliable predictors of response, with large variations
in the c value across the algorithms. Many of them have no (c < 0.6),
poor (0.6≤ c < 0.7), or fair (0.7≤ c < 0.8) predictive capabilities. As
an example of excellent predictive abilities of K trans at V2 and its
percentage change (V21) across all algorithms, Figure 7 presents
the scatter plots of mean tumor K trans values at V1 (Figure 7A),
V2 (Figure 7B), and their percentage changes (Figure 7C ) obtained
by all algorithms from the 10 patients. While there are clear overlaps
in K trans values at baseline (V1) between pCRs and non-pCRs, the
separations of the two groups are quite remarkable using V2 K trans
and K trans percentage change values obtained by almost all the algo-
rithms. The same patterns are observed for the kep parameter.
Figure 8 shows the color tumor K trans maps of a non-pCR
(Figure 8A) and a pCR (Figure 8B) at V1 and V2, computed and
generated by all 12 algorithms. For each DCE-MRI data set, the
parametric maps are generated for all tumor ROIs on multiple image
slices. The K trans maps presented in Figure 8 are from the same
image slice (for each subject at each visit) through the center of
the tumor. Note that except for the algorithms of BWH-GE_TM
and BWH-GE_ETM, all K trans maps are overlaid on post-contrast
images. Despite the differences in software algorithms/tools and dis-
play color scales, one observation is apparent and common on all the
K trans maps: the minimal change in the tumor K trans map from V1 to
V2 for the non-pCR is in stark contrast with the dramatic “cooling”
of the K trans map color—red to blue (decrease in value)—from V1 to
V2 for the pCR. The color kep maps (not shown here) show nearly
identical patterns for the same two patients.
Discussion
Though DCE-MRI is becoming one of the imaging modalities of
choice for assessment of cancer therapy response in early phase
clinical trials, systematic comparison and validation of methods for
pharmacokinetic analysis of DCE-MRI time-course data are needed
to determine sources of parameter errors and variations, examine the
effects of these variations on evaluation of tumor therapy response,
and reach consensus on the best practice for DCE-MRI in a multi-
center clinical trial. To the best of our knowledge, this is the first
study in which shared DCE-MRI data from a longitudinal therapy
monitoring study are analyzed by multiple centers using site-specific
pharmacokinetic models and associated algorithms. The overall
purpose of this multicenter DCE-MRI data analysis challenge is to
evaluate variations in DCE-MRI prediction of breast cancer therapy
response that are caused by differences in pharmacokinetic models
and associated software algorithms only.
With the exception of the 2 SSM algorithms, the other 10 algo-
rithms employed in this challenge are the commonly used TM and
ETM. The reasonable results from fittings of the TM-simulated
DRO data with five of the six involved TM algorithms confirm
the accuracy of mathematical formulation and software coding in
these TM software packages. The large errors (>20%) in estimated
K trans were mostly resulted from fittings of DRO data with high
K trans and low ve combinations, which were generally not the cases
for the studied breast tumors. Though the reasons for large errors from
these particular K trans and ve combinations warrant further investiga-
tions, a complete and in-depth analysis of the DRO data-fitting results
is beyond the scope of this manuscript. Despite the fixed inputs of
tumor ROI definition, AIF, and T 10 in analyzing the shared human
data for all algorithms, there are substantial variations in returned
Table 6. DCE-MRI Parameter ULR c-Statistic Values for Early Prediction of Pathologic Response.
Parameter Algorithm V1 V2 % Change (V21)
K trans OHSU_TM 0.667 0.952 0.952
VU_TM 0.571 1 0.952
ISM_TM 0.619 0.81 0.905
BWH-GE_TM 0.595 1 1
UP_TM 0.619 0.786 1
BWH-3D Slicer_TM 0.524 1 1
VU_ETM 0.524 0.952 0.762
UM_ETM 0.714 0.857 1
BWH-GE_ETM 0.786 1 1
UW_ETM 0.762 0.905 1
OHSU_SSM 0.571 1 0.857
VU_SSM 0.476 1 0.81
ve OHSU_TM 0.81 0.762 0.667
VU_TM 0.571 0.762 0.595
ISM_TM 0.667 0.81 0.81
BWH-GE_TM 0.595 0.857 0.905
UP_TM 0.643 0.81 0.857
BWH-3D Slicer_TM 0.762 0.81 0.952
VU_ETM 0.667 0.667 0.452
UM_ETM 0.619 0.643 0.5
BWH-GE_ETM 0.548 1 0.905
UW_ETM 0.667 1 0.857
OHSU_SSM 0.667 0.81 0.714
VU_SSM 0.714 0.714 0.5
kep OHSU_TM 0.5 1 0.952
VU_TM 0.762 0.81 1
ISM_TM 0.5 0.952 0.905
BWH-GE_TM 0.81 1 1
UP_TM 0.667 1 0.952
BWH-3D Slicer_TM 0.667 0.952 1
VU_ETM 0.619 0.714 0.81
UM_ETM 0.738 0.857 1
BWH-GE_ETM 0.81 1 1
UW_ETM 0.762 1 1
OHSU_SSM 0.476 1 0.905
VU_SSM 0.571 0.81 0.857
vp VU_ETM 0.571 0.619 0.571
UM_ETM 0.857 0.905 0.405
BWH-GE_ETM 0.476 0.857 0.643
UW_ETM 0.667 0.714 0.667
τi OHSU_SSM 0.857 0.571 0.952
VU_SSM 0.452 0.548 0.548
% Change (V21), percentage change (V2 relative to V1).
Note: The institution abbreviation is listed ahead of the model abbreviation.
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DCE-MRI parameters. When comparing all 12 algorithms, the main
contributions to the variations of the two common parameters, K trans
and ve, are the large values returned by the two SSM algorithms and
small values returned by the BWH-3D Slicer TM software tool, with
the latter returning K trans values two to three times and ve value three
to four times smaller than the other algorithms (Figure 4A). It is not
surprising that K trans and ve parameters derived from SSM analysis are
significantly greater than their TM or ETM counterparts at either V1
or V2 (Figure 6 and Table 5), as the same patterns have been observed
in DCE-MRI studies of tumors in different organs [17,27,31–33,37–
39]. The differences between the SSM and TM in derived K trans and
ve parameter values are systematic ones directly resulted from inclusion
or exclusion of the water exchange effects by the SSM and TM, respec-
tively. The exact reason for the out-of-range small K trans and ve values
returned by the BWH-3D Slicer TM algorithm is unclear. DRO data
fitting by the same algorithm consistently returned K trans and ve values
with >10% errors for all combinations of simulated K trans and ve values
with maximum error of 71% for K trans estimation. Heye et al. observed
up to 10-fold to 100-fold difference in K trans and ve values obtained
with different commercial software packages [22]. They attributed these
massive discrepancies to possible differences in scaling factors used by
commercial vendors for reporting or displaying estimated pharmaco-
kinetic parameters. The same reason may be the cause of the two-fold
to four-fold parameter value difference observed in this study between
the BWH-3D Slicer TM software tool and most other algorithms.
Most of the DCE-MRI parametric maps generated from the shared
human data were spatially heterogeneous (Figure 8) as a result of breast
tumor heterogeneity. The difference in computing tumor mean param-
eter values by each algorithm—averaging pixel parameter values or
averaging slice ROI parameter values (Table 1)—is another cause of
parameter variance.
It is reasonable that the agreement in the three common DCE-MRI
parameters (K trans, ve, and kep) that are obtainable by all three kinetic
models is generally improved when only algorithms within the same
kinetic model are compared, as opposed to comparisons across all
12 algorithms (Table 2). However, there are still substantial variations
in returned parameter values by different software tools based on the
same model. Besides the scaling factor variation that may have con-
tributed to the markedly small K trans and ve values obtained with the
BWH-3D Slicer TM algorithm, other contributions to parameter
variations among algorithms based on the same model may come
from differences in fixed physiological and MR parameters (such as
hematocrit, pre-contrast blood T1, and so on), contrast arrival time
(or AIF shift), AIF curve resampling strategy, and goodness of fitting
criteria employed in each algorithm. These factors were not controlled
for any algorithm used in this data analysis challenge. It should be
noted that the BWH-3D Slicer tool is the only one of the tested soft-
ware packages that is available as free open source software. Availability
of the software source code can facilitate reproducibility of results [40]
and aid further investigation of sources of variability and inconsistency
in comparison with other algorithm implementations.
One important observation that is not available in the study by
Heye et al. [22] but is afforded by the longitudinal nature of the
shared DCE-MRI data in this study is the agreement in parameter
percentage change (V2 relative to V1) among the algorithms. It is
interesting and important to note that agreements in parameter
percentage changes are generally better than those of the absolute pa-
rameter values at either V1 or V2 regardless whether the comparisons
are made across all algorithms or within each kinetic model (Figure 4
and Tables 2, 3, and 4). The CCC values of K trans at V1 and V2 are
quite small for any pairwise comparison of TM algorithms that
includes the BWH-3D Slicer TM algorithm, but those of the
Figure 7. Scatter plots of mean tumor K trans at V1 (A), V2 (B), and its percentage change (V21) (C) for three pCRs (black circles) and seven
non-pCRs (red triangles). Each column represents results returned by one data analysis algorithm. The columns associated with the
same kinetic model are grouped together (labeled in A), as explained in Figure 4.
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corresponding K trans percentage changes are drastically increased
(Table 3), indicating greater agreement between the pair of algo-
rithms. The reason for such improvement in agreement among the
algorithms is probably partial cancellation of systematic differences
(or variations) among different algorithms in percentage change calcula-
tions. For example, if the application of a scaling factor in the BWH-3D
Slicer TM algorithm caused unusually small K trans and ve values, the
effects of the scaling factor were canceled in calculating percentage
changes of these parameters, resulting in percentage change values
comparable to those obtained with the other algorithms.
Among the 12 algorithms used in this challenge, only the 4 based
on the ETM generate the vp parameter through data fitting. Com-
pared to the K trans and ve parameters estimated with these four ETM
algorithms, the variance in vp is relatively high, reflected by its large
wCV (Figure 5), small ICC (see above), and small CCC (Table 4)
values. This is most likely due to the relatively low temporal resolution
Figure 8. V1 and V2 single slice tumor K trans parametric maps generated by all 12 algorithms for a non-pCR (A) and a pCR (B). The
primary tumor was in the left breast of the non-pCR and the right breast of the pCR. The color K trans maps are overlaid on post-contrast
or pre-contrast DCE images. Although the color scales for these maps are different between subjects and among algorithms, they are
kept the same for V1 and V2 maps generated by the same algorithm for the same subject.
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(∼20 seconds) of the raw breast DCE-MRI data. vp is a parameter
of the vascular compartment that contributes a significant fraction
of the DCE-MRI signal only during the early phase of rapid signal rise.
The inability of the data acquisition protocol used in this study to
accurately capture the DCE curve shape during this time window
leads to low accuracy and precision in vp quantification [20,21] and
hence its high variance. A simulation study [41] shows that at least
4-second temporal resolution is needed for accurate vp estimation
from breast DCE-MRI data. Given clinical preference for full breast
coverage and high spatial resolution in breast MRI, such high temporal
resolution is difficult to achieve even with combined use of k-space
undersampling scheme and parallel imaging acceleration, as is the case
for the shared breast data in this study. The low accuracy and precision
of the vp parameter, and possibly the resultant reduced capability in
prediction of therapy response found (see below) in this study, dem-
onstrate the importance of proper model selection for pharmacokinetic
analysis of DCE-MRI data. Using a model that includes the vascular
compartment to fit low temporal resolution DCE-MRI data will intro-
duce more errors and uncertainties in the derived parameters [20,21]
and thus diminish the effectiveness of DCE-MRI for evaluation of
therapy response.
Despite the considerable variances in parameter values obtained
with different algorithms, it is rather encouraging within the context
of therapy response assessment, however, that nearly all 12 algo-
rithms provided good to excellent (ULR c ≥ 0.8) early prediction of
pathologic response using V2 K trans and kep or their corresponding
percentage changes (V2 relative to V1) as predictive markers (Table 6).
For V2 K trans and kep, there are 9 and 8 (of 12) algorithms providing
excellent predictions with ULR c ≥ 0.9, respectively, while for K trans
and kep percentage changes, the numbers of algorithms with ULR c ≥
0.9 are 9 and 10 (of 12), respectively. The predictive abilities of the
V2 K trans and kep parameters across all algorithms may be due to 1)
the substantial decreases in perfusion and permeability of the three
pCR tumors in comparison with the seven non-pCR tumors out-
weighed parameter variations introduced by algorithm differences,
and/or 2) the interalgorithm variations are systematic, i.e., error signs
in parameter misestimations are the same for both pCR and non-pCR
tumors: overestimation or underestimation for both groups. The
second, potentially the most important, reason is clearly illustrated in
Figure 7B for V2 K trans, where the black (pCR) and red (non-pCR)
data points more or less move in the same up or down direction going
from one algorithm to another, maintaining similar pCR versus non-
pCR data point gaps among the algorithms and thus similar dis-
criminative capabilities. The predictive capabilities of K trans and kep
percentage changes across all algorithms are most likely due to
cancellation of the interalgorithm systematic errors (or variations)
in percentage change calculation. Figure 7C shows relatively stable
distribution of K trans percentage changes for both pCRs and non-
pCRs across the 12 algorithms in contrast to absolute V1 (Figure 7A)
and V2 (Figure 7B) K trans values that are more variable across algo-
rithms. Similar patterns can also be seen in Figure 4. With less system-
atic errors (variations), the more stable K trans and kep percentage change
values allowed the tested algorithms to estimate the intrinsic differences
between the pCRs and non-pCRs and gave fairly uniform predictions
of therapy response.
In this multicenter data analysis challenge, the three major aspects
in DCE-MRI data acquisition and analysis that can cause significant
parameter variations (i.e., tumor ROI definition, T 10 measurement,
and AIF determination) were controlled to focus on comparisons of
pharmacokinetic models and associated algorithms in assessment of
breast cancer response to NACT. The results suggest that variations
in DCE-MRI parameters caused by differences in models/algorithms
only are mostly systematic. As a result, all models/algorithms per-
formed fairly consistently in prediction of therapy response, especially
using the percentage change metrics in which the interalgorithm
systematic variations are significantly reduced. In this particular study
setting, K trans and kep percentage changes computed with most of the
algorithms provided excellent early prediction of breast cancer re-
sponse to NACT. The introduction of variations in tumor ROI defi-
nition and errors in T 10 and AIF determinations in a multicenter
clinical trial setting where DCE-MRI data are acquired and analyzed
at each individual site will add random errors and variations in derived
DCE-MRI parameters. This will not only cause more severe param-
eter variance but also affect DCE-MRI performance in evaluation of
therapy response. Therefore, it is of paramount importance in a multi-
center clinical trial to strictly standardize data acquisition protocol
(such as temporal resolution) and perform frequent scanner quality
assurance/quality control (QA/QC) [9–11] to minimize interscanner
platform or interacquisition protocol random errors in quantification
of T 10 and AIF in a longitudinal DCE-MRI study of tumor therapy
response. Random errors due to variations in manual drawing of tumor
ROI are difficult to avoid. Use of automatic or semiautomatic algo-
rithms for tumor ROI definition may help mitigate such errors. One
possible approach to reduce random errors and variations in a multi-
center trial and improve performance consistency in response assess-
ment is centralized DCE-MRI data analysis in which fixed inputs for
pharmacokinetic modeling, such as single observer-defined tumor ROIs
and population-averaged AIF, could be used.
In conclusion, considerable parameter variations were observed
when shared breast DCE-MRI data sets were analyzed with different
algorithms based on the TM, ETM, and SSM in a multicenter data
analysis challenge. However, nearly all algorithms provided good to
excellent early prediction of breast cancer response to therapy using
the K trans and kep parameters after the first cycle of NACT and their
percentage changes, suggesting that the utility of DCE-MRI for
assessment of therapy response is not diminished by interalgorithm
systematic variations.
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